191 related articles for article (PubMed ID: 36291699)
1. Combination of Antimalarial and CNS Drugs with Antineoplastic Agents in MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action.
Duarte D; Nunes M; Ricardo S; Vale N
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291699
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs.
Duarte D; Cardoso A; Vale N
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299028
[TBL] [Abstract][Full Text] [Related]
3. Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells.
Duarte D; Rêma A; Amorim I; Vale N
Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204691
[TBL] [Abstract][Full Text] [Related]
4. New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells.
Duarte D; Vale N
Biomolecules; 2020 Dec; 10(12):. PubMed ID: 33271968
[TBL] [Abstract][Full Text] [Related]
5. Honeybee Venom Synergistically Enhances the Cytotoxic Effect of CNS Drugs in HT-29 Colon and MCF-7 Breast Cancer Cell Lines.
Duarte D; Falcão SI; El Mehdi I; Vilas-Boas M; Vale N
Pharmaceutics; 2022 Feb; 14(3):. PubMed ID: 35335887
[TBL] [Abstract][Full Text] [Related]
6. Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells.
Duarte D; Guerreiro I; Vale N
Curr Issues Mol Biol; 2022 Oct; 44(10):4930-4949. PubMed ID: 36286050
[TBL] [Abstract][Full Text] [Related]
7. A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells.
Pellegrini E; Multari G; Gallo FR; Vecchiotti D; Zazzeroni F; Condello M; Meschini S
Toxicol Appl Pharmacol; 2022 Jan; 434():115816. PubMed ID: 34856211
[TBL] [Abstract][Full Text] [Related]
8. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
9. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
Schneiderman RS; Shmueli E; Kirson ED; Palti Y
BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
[TBL] [Abstract][Full Text] [Related]
10. Increasing the cytotoxicity of doxorubicin in breast cancer MCF-7 cells with multidrug resistance using a mesoporous silica nanoparticle drug delivery system.
Wang X; Teng Z; Wang H; Wang C; Liu Y; Tang Y; Wu J; Sun J; Wang H; Wang J; Lu G
Int J Clin Exp Pathol; 2014; 7(4):1337-47. PubMed ID: 24817930
[TBL] [Abstract][Full Text] [Related]
11. Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.
Chen Q; Liu X; Luo Z; Wang S; Lin J; Xie Z; Li M; Li C; Cao H; Huang Q; Mao J; Xu B
J Cell Physiol; 2019 May; 234(5):6611-6623. PubMed ID: 30230544
[TBL] [Abstract][Full Text] [Related]
12. How Antimalarials and Antineoplastic Drugs can Interact in Combination Therapies: A Perspective on the Role of PPT1 Enzyme.
Duarte D; Vale N
Curr Drug Metab; 2021; 22(13):1009-1016. PubMed ID: 34791996
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative efficacies but minor drug transporter inducing effects of paclitaxel, cisplatin, or 5-fluorouracil in a murine xenograft model for head and neck squamous cell carcinoma.
Theile D; Gal Z; Warta R; Rigalli JP; Lahrmann B; Grabe N; Herold-Mende C; Dyckhoff G; Weiss J
Cancer Biol Ther; 2014 Apr; 15(4):436-42. PubMed ID: 24448417
[TBL] [Abstract][Full Text] [Related]
14. Enhanced lysosomal function is critical for paclitaxel resistance in cancer cells: reversed by artesunate.
Li Z; Zhu YT; Xiang M; Qiu JL; Luo SQ; Lin F
Acta Pharmacol Sin; 2021 Apr; 42(4):624-632. PubMed ID: 32704040
[TBL] [Abstract][Full Text] [Related]
15. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y
Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834
[TBL] [Abstract][Full Text] [Related]
16. Curcumin Reverses 5-Fluorouracil Resistance by Promoting Human Colon Cancer HCT-8/5-FU Cell Apoptosis and Down-regulating Heat Shock Protein 27 and P-Glycoprotein.
He WT; Zhu YH; Zhang T; Abulimiti P; Zeng FY; Zhang LP; Luo LJ; Xie XM; Zhang HL
Chin J Integr Med; 2019 Jun; 25(6):416-424. PubMed ID: 30484020
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil.
Vinod BS; Antony J; Nair HH; Puliyappadamba VT; Saikia M; Narayanan SS; Bevin A; Anto RJ
Cell Death Dis; 2013 Feb; 4(2):e505. PubMed ID: 23429291
[TBL] [Abstract][Full Text] [Related]
18. Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein.
Wang S; Wang L; Shi Z; Zhong Z; Chen M; Wang Y
PLoS One; 2014; 9(5):e97512. PubMed ID: 24830744
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
Vale N; Pereira M; Santos J; Moura C; Marques L; Duarte D
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
